drugset
drugset / Trial / NCT05502237

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237 ↗

Phase 3 Active not recruiting 1021 enrolled Gilead Sciences Arcus Biosciences, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.

Timeline

Start
2022-10-12
Primary completion
2028-06
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Domvanalimab Monoclonal antibody 1200 mg Intravenous
Comparator Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Zimberelimab Monoclonal antibody 360 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Paclitaxel Small molecule 100 mg/m2 Intravenous
Background Paclitaxel Small molecule 200 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma